Supernus Pharmaceuticals (SUPN) Net Cash Flow (2011 - 2026)
Supernus Pharmaceuticals (SUPN) posted quarterly Net Cash Flow of -$4.9 million for Q2 2026, down 117.03% year-over-year from $28.9 million in Q2 2025, and down 108.71% on a QoQ basis from $56.4 million in Q1 2026.
Supernus Pharmaceuticals (SUPN) Net Cash Flow (2011 - 2026) Analysis & Trends
Supernus Pharmaceuticals has reported Net Cash Flow for 16 years, with the latest figure at -$4.9 million in Q2 2026.
- Net Cash Flow for Q2 2026 came in at -$4.9 million, down 117.03% year-over-year; the trailing twelve-month figure through Jun 2026 was $36.7 million (down 60.39% YoY), and the FY2025 annual result was $60.6 million, up 1158.31% from the prior year.
- Net Cash Flow eased to -$4.9 million in Q2 2026, from $56.4 million in the prior quarter.
- Over five years, Net Cash Flow peaked at $369.1 million in Q1 2023 and troughed at -$437.5 million in Q2 2023.
- A 5-year average of -$1.2 million and a median of -$8.1 million in 2024 frame the typical range for Net Cash Flow.
- The largest YoY upside for Net Cash Flow was 520.75% in 2023 against a maximum downside of 858.05% in 2023.
- A 5-year view of Net Cash Flow shows it stood at -$18.4 million in 2022, then declined by 8.49% to -$19.9 million in 2023, then soared by 288.94% to $37.7 million in 2024, then sank by 160.87% to -$22.9 million in 2025, then soared by 78.55% to -$4.9 million in 2026.
- Per Business Quant data, the three most recent Net Cash Flow figures were -$4.9 million in Q2 2026, $56.4 million in Q1 2026, and -$22.9 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.94 Bn | 42.97 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.08 Bn | 39.43 Bn | 2.15 Bn | -81.00 Mn |
| 3 | Zoetis | 31.54 Bn | 29.87 Bn | 1.05 Bn | -458.00 Mn |
| 4 | Takeda Pharmaceutical | 28.60 Bn | 22.80 Bn | 5.10 Bn | -881.03 Mn |
| 5 | United Therapeutics | 22.12 Bn | 19.46 Bn | 683.80 Mn | 523.50 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | -912.40 Mn |
| 7 | Neurocrine Biosciences | 15.50 Bn | 15.11 Bn | 935.80 Mn | 64.40 Mn |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn | 93.00 Mn |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - | - |
| 10 | Supernus Pharmaceuticals | 2.74 Bn | 2.37 Bn | 185.39 Mn | -4.92 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -4.92 Mn |
| Jun 30, 2026 | -4.92 Mn |
| Mar 31, 2026 | 56.42 Mn |
| Mar 31, 2026 | 56.42 Mn |
| Dec 31, 2025 | -22.92 Mn |
| Dec 31, 2025 | -22.92 Mn |
| Sep 30, 2025 | 8.11 Mn |
| Sep 30, 2025 | 8.11 Mn |
| Jun 30, 2025 | 28.86 Mn |
| Jun 30, 2025 | 28.86 Mn |
| Mar 31, 2025 | 46.52 Mn |
| Mar 31, 2025 | 46.52 Mn |
| Dec 31, 2024 | 37.66 Mn |
| Dec 31, 2024 | 37.66 Mn |
| Sep 30, 2024 | -20.42 Mn |
| Sep 30, 2024 | -20.42 Mn |
| Jun 30, 2024 | -11.31 Mn |
| Jun 30, 2024 | -11.31 Mn |
| Mar 31, 2024 | -11.65 Mn |
| Mar 31, 2024 | -11.65 Mn |